Central Valley Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$240K Sell
207
-103
-33% -$122K 0.06% 145
2026
Q2
$372K Sell
310
-1
-0.3% -$1.02K 0.1% 139
2026
Q1
$286K Buy
311
+101
+48% +$102K 0.08% 153
2025
Q4
$226K Buy
+210
New +$201K 0.07% 141
2024
Q2
– Sell
-314
Closed -$245K – 169
2024
Q1
$245K Buy
+314
New +$223K 0.13% 127

Other funds holding LLY

Central Valley Advisors's LLY Position: Q3 2026 in Review

Central Valley Advisors reduced its Eli Lilly (LLY) stake by 33% in Q3 2026, selling an estimated $122K and leaving 207 shares worth $240K. The position accounts for 0.06% of the portfolio, ranked #145.

Central Valley Advisors first reported a position in LLY in Q1 2024 and has held it in 5 quarters since. The position peaked at $372K in Q2 2026. 4,568 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Central Valley Advisors held 207 shares of Eli Lilly worth $240K as of Q3 2026.
  • Central Valley Advisors sold 103 Eli Lilly shares in Q3 2026, an estimated $122K.
  • Eli Lilly made up 0.06% of Central Valley Advisors's portfolio in Q3 2026, its #145 holding.
  • Central Valley Advisors first reported a position in Eli Lilly in Q1 2024 and has held it in 5 quarters since.
  • Central Valley Advisors's Eli Lilly position peaked at $372K in Q2 2026.
  • 4,568 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Central Valley Advisors's 13F filing for Q3 2026, filed 27 Oct 2026.